147 related articles for article (PubMed ID: 15327403)
21. Preservation of kidney function with combined inhibition of NADPH oxidase and angiotensin-converting enzyme in diabetic nephropathy.
Thallas-Bonke V; Coughlan MT; Bach LA; Cooper ME; Forbes JM
Am J Nephrol; 2010; 32(1):73-82. PubMed ID: 20551625
[TBL] [Abstract][Full Text] [Related]
22. The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome.
Konda T; Enomoto A; Matsushita J; Takahara A; Moriyama T
Nephron Physiol; 2005; 101(1):p1-13. PubMed ID: 15886499
[TBL] [Abstract][Full Text] [Related]
23. Amlodipine in the Era of New Generation Calcium Channel Blockers.
Tiwaskar M; Langote A; Kashyap R; Toppo A
J Assoc Physicians India; 2018 Mar; 66(3):64-9. PubMed ID: 30341872
[TBL] [Abstract][Full Text] [Related]
24. Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats.
Du J; Fan YY; Hitomi H; Kiyomoto H; Kimura S; Kong CZ; Noma T; Kohno M; Nishiyama A; Nakano D
Am J Physiol Renal Physiol; 2009 Sep; 297(3):F802-8. PubMed ID: 19535572
[TBL] [Abstract][Full Text] [Related]
25. Effect of calcium channel blockade on adrenergically induced renal vasoconstriction in rat models of renal impairment.
Khan AH; Sattar MA; Abdullah NA; Johns EJ
Clin Exp Pharmacol Physiol; 2009 May; 36(5-6):501-8. PubMed ID: 19673932
[TBL] [Abstract][Full Text] [Related]
26. Ethyl pyruvate ameliorates albuminuria and glomerular injury in the animal model of diabetic nephropathy.
Ju KD; Shin EK; Cho EJ; Yoon HB; Kim HS; Kim H; Yang J; Hwang YH; Ahn C; Oh KH
Am J Physiol Renal Physiol; 2012 Mar; 302(5):F606-13. PubMed ID: 22129969
[TBL] [Abstract][Full Text] [Related]
27. Lumbrokinase attenuates diabetic nephropathy through regulating extracellular matrix degradation in Streptozotocin-induced diabetic rats.
Sun H; Ge N; Shao M; Cheng X; Li Y; Li S; Shen J
Diabetes Res Clin Pract; 2013 Apr; 100(1):85-95. PubMed ID: 23384615
[TBL] [Abstract][Full Text] [Related]
28. Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes.
Qin J; Zhang Z; Liu J; Sun L; Hu L; Cooper ME; Cao Z
Kidney Int; 2003 Aug; 64(2):565-71. PubMed ID: 12846751
[TBL] [Abstract][Full Text] [Related]
29. Pharmacodynamic interaction between mibefradil and other calcium channel blockers.
Matthes J; Huber I; Haaf O; Antepohl W; Striessnig J; Herzig S
Naunyn Schmiedebergs Arch Pharmacol; 2000 Jun; 361(6):578-83. PubMed ID: 10882031
[TBL] [Abstract][Full Text] [Related]
30. Effects of benazepril on renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in diabetic rats.
Sun SZ; Wang Y; Li Q; Tian YJ; Liu MH; Yu YH
Chin Med J (Engl); 2006 May; 119(10):814-21. PubMed ID: 16732983
[TBL] [Abstract][Full Text] [Related]
31. Reduction of aldosterone production improves renal oxidative stress and fibrosis in diabetic rats.
Matavelli LC; Siragy HM
J Cardiovasc Pharmacol; 2013 Jan; 61(1):17-22. PubMed ID: 23011470
[TBL] [Abstract][Full Text] [Related]
32. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
Taira M; Toba H; Murakami M; Iga I; Serizawa R; Murata S; Kobara M; Nakata T
Eur J Pharmacol; 2008 Jul; 589(1-3):264-71. PubMed ID: 18582458
[TBL] [Abstract][Full Text] [Related]
33. Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy.
Sasaki H; Saiki A; Endo K; Ban N; Yamaguchi T; Kawana H; Nagayama D; Ohhira M; Oyama T; Miyashita Y; Shirai K
J Atheroscler Thromb; 2009 Oct; 16(5):568-75. PubMed ID: 19749494
[TBL] [Abstract][Full Text] [Related]
34. Renoprotective effect of N-type Ca channel blockade in diabetic nephropathy.
Fujisawa T; Ikegami H; Noso S; Hiromine Y; Kawabata Y; Nishino M; Asano K; Ogihara T
J Diabetes Complications; 2007; 21(4):252-7. PubMed ID: 17616356
[TBL] [Abstract][Full Text] [Related]
35. Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure.
Komers R; Oyama TT; Beard DR; Tikellis C; Xu B; Lotspeich DF; Anderson S
Kidney Int; 2011 Feb; 79(4):432-42. PubMed ID: 20962741
[TBL] [Abstract][Full Text] [Related]
36. Omega-3 fatty acid rich diet prevents diabetic renal disease.
Garman JH; Mulroney S; Manigrasso M; Flynn E; Maric C
Am J Physiol Renal Physiol; 2009 Feb; 296(2):F306-16. PubMed ID: 19052104
[TBL] [Abstract][Full Text] [Related]
37. Comparison of sympathetic modulation induced by single oral doses of mibefradil, amlodipine, and nifedipine in healthy volunteers.
Ragueneau I; Sao AB; Démolis JL; Darné B; Funck-Brentano C; Jaillon P
Clin Pharmacol Ther; 2001 Mar; 69(3):122-9. PubMed ID: 11240976
[TBL] [Abstract][Full Text] [Related]
38. Role of sympathetic nerves in the differential effects of T-type and L-type calcium channel blockers on renin secretion and renin gene expression.
Hinder M; Wagner C; Krämer BK; Kurtz A
Nephrol Dial Transplant; 1999; 14 Suppl 4():44-5. PubMed ID: 10463214
[No Abstract] [Full Text] [Related]
39. Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases.
McLennan SV; Kelly DJ; Cox AJ; Cao Z; Lyons JG; Yue DK; Gilbert RE
Diabetologia; 2002 Feb; 45(2):268-75. PubMed ID: 11935159
[TBL] [Abstract][Full Text] [Related]
40. Reduction of albuminuria by angiotensin receptor blocker beyond blood pressure lowering: evaluation in megsin/receptor for advanced glycation end products/inducible nitric oxide synthase triple transgenic diabetic nephropathy mouse model.
Ohtomo S; Ito M; Izuhara Y; Van Ypersele De Strihou C; Miyata T
Nephrology (Carlton); 2008 Dec; 13(6):517-21. PubMed ID: 18363646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
